Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C
dc.contributor.author | Snow, Kristin K. | en_US |
dc.contributor.author | Bonkovsky, Herbert L. | en_US |
dc.contributor.author | Fontana, Robert John | en_US |
dc.contributor.author | Kim, H. -Y. | en_US |
dc.contributor.author | Sterling, Richard K. | en_US |
dc.contributor.author | Di Bisceglie, Adrian M. | en_US |
dc.contributor.author | Morgan, Timothy R. | en_US |
dc.contributor.author | Dienstag, Jules L. | en_US |
dc.contributor.author | Ghany, Marc G. | en_US |
dc.date.accessioned | 2011-01-31T17:47:54Z | |
dc.date.available | 2011-06-09T15:09:40Z | en_US |
dc.date.issued | 2010-04 | en_US |
dc.identifier.citation | Snow, K. K.; Bonkovsky, H. L.; Fontana, R. J.; Kim, H.-Y.; Sterling, R. K.; Di Bisceglie, A. M.; Morgan, T. R.; Dienstag, J. L.; Ghany, M. G.; (2010). "Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C." Alimentary Pharmacology & Therapeutics 31(7): 719-734. <http://hdl.handle.net/2027.42/79272> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79272 | |
dc.description.abstract | Aliment Pharmacol Ther 31 , 719–734Primary analysis of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial showed long-term peginterferon therapy did not reduce complications in patients with chronic hepatitis C and advanced fibrosis or cirrhosis.To assess the effects of long-term peginterferon therapy and disease progression on health-related quality of life (HRQOL), symptoms and sexual health in HALT-C patients.A total of 517 HALT-C patients received peginterferon alfa-2a (90 μg/week); 532 received no additional treatment for 3.5 years. Patients were followed up for outcomes of death, hepatocellular carcinoma and hepatic decompensation. Sexual health, SF-36 scores and symptoms were serially assessed by repeated-measures analyses of covariance.Patients with cirrhosis ( n = 427) reported lower general well-being and more fatigue ( P < 0.001) than patients with fibrosis ( n = 622). Physical scores declined significantly over time, independent of treatment, and patients with cirrhosis reported lower scores. Vitality scores were lower in those with cirrhosis, and treated patients experienced a greater decline over time than untreated patients; HRQOL rebounded after treatment ended. Patients with a clinical outcome had significantly greater declines in all SF-36 and symptom scores. Among men, Sexual Health scores were significantly worse in treated patients and in those with a clinical outcome.Clinical progression of chronic hepatitis C and maintenance peginterferon therapy led to worsening of symptoms, HRQOL and, in men, sexual health in a large patient cohort followed up over 4 years (NCT00006164). | en_US |
dc.format.extent | 397808 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.title | Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | New England Research Institutes, Watertown, MA, USA | en_US |
dc.contributor.affiliationother | Departments of Medicine and Molecular & Structural Biology and The Liver-Biliary-Pancreatic Center, University of Connecticut Health Center, Farmington, CT, USA | en_US |
dc.contributor.affiliationother | Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA, USA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO, USA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, University of California – Irvine, Irvine, CA and Gastroenterology Service, VA Long Beach Healthcare System, Long Beach, CA, USA | en_US |
dc.contributor.affiliationother | Gastrointestinal Unit (Medical Services), Massachusetts General Hospital and the Department of Medicine, Harvard Medical School, Boston, MA, USA | en_US |
dc.contributor.affiliationother | Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA | en_US |
dc.identifier.pmid | 20070284 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79272/1/j.1365-2036.2010.04235.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2036.2010.04235.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.